The road map sets global targets and milestones to prevent, control, eliminate or eradicate 20 diseases and disease groups as well as cross-cutting targets aligned with the Sustainable Development Goals. Three foundational pillars will support global efforts to achieve the targets: accelerate progra...mmatic action (pillar 1), intensify cross-cutting approaches (pillar 2) and change operating models and culture to facilitate country ownership (pillar 3).
more
This companion document to Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021-2030 ("the road map") aims to support a range of stakeholders - including countries in which neglected tropical diseases (NTDs) are endemic, international organi...zations and non-State actors - to achieve the road map targets through a transdisciplinary, cross-cutting One Health approach. Specifically, it provides guidance on the One Health actions needed by major stakeholders and how to support a paradigm shift towards One Health in national NTD programmes. Examples of common One Health challenges and how they can be overcome as well as illustrative cases studies are provided throughout. The companion document was developed through a global consultative process involving stakeholder interviews, interactive workshops, and online public consultation.
more
Accessed on 04.04.2023
Die Initiative Medikamente gegen vernachlässigte Krankheiten (Drugs for Neglected Diseases initiative, DNDi) ist eine internationale gemeinnützige Organisation, die sichere, wirksame und bezahlbare Behandlungen für die am meisten vernachlässigten Patient:innen erforsch...t, entwickelt und bereitstellt.
more
Accessed on 04.04.2023
A Iniciativa Medicamentos para Doenças Negligenciadas (DNDi) é uma organização
internacional sem fins lucrativos que disponibiliza medicamentos seguros, eficazes
e acessíveis para doenças negligenciadas, desde o laboratório até sua chegada às
mãos das popula...ções mais vulneráveis do mundo.
more
Website last accessed on 09.04.2023
Youtube Video - Documentário Doença de Chagas
Website last accessed on 09.04.2023
Donors making a difference: Eliminating neglected tropical diseases and other outbreaks (Websites WHO 14. June 2022)
Driving progress towards rabies elimination: Results of Gavi’s Learning Agenda on rabies and new WHO position on rabies immunization
Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. It is a significant public health problem, affecting millions of people worldwide. And although it was described 110 years ago, only two old nitroheterocyclic drugs, benznidazole and nifurtimox, are cu...rrently available for the treatment of Chagas disease and both have several limitations. Besides the clear unmet medical need, many challenges preclude the development of new treatments, some of them related to a lack of understanding of the pathophysiology of the disease and parasite-host interactions. New knowledge and tools are becoming available, but the number of new chemical entities progressing through the preclinical pipeline is inadequate. Therefore, it is still uncertain whether safe, effective and accessible new drugs will be available in the near future. The Chagas disease research community must commit to even greater collaboration to ensure that patients eventually benefit from better treatments.
more
Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT... has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host−parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.
more
Website last accessed on 10.04.2023
The Chagas disease is frequently referred to as the effects that the parasite Trypanosoma cruzi (T. cruzi) has on people’s health. However, from our perspective, Chagas is much more than that: it is a complex socioenvironmental health problem in which elemen...ts of different nature converge and interact. The biomedical and epidemiological aspects, which are most frequently addressed, are only a piece of the puzzle that needs to be complete in order to understand Chagas in all its complexity. Social, environmental, economic, political, cultural, and educational elements turn out to be essential in comprehending the magnitude of the problem without prejudice or stigmatizations.
more
Preventive chemotherapy with praziquantel (PZQ) is the cornerstone of schistosomiasis control. However, a single dose of PZQ (40 mg/kg) does not cure all infections. Repeated doses of PZQ at short intervals might increase efficacy in terms of cure rate (CR) and intensity reduction rate (IRR). Here, ...we determined the efficacy of a single versus four repeated treatments with PZQ on Schistosoma mansoni infection in school-aged children from Côte d'Ivoire, using two different diagnostic tests.
more
Website last accessed on 10.04.2023
Investing to overcome the global impact of neglected tropical diseases charts new ground in tackling the 17 neglected tropical diseases (NTDs) that aff ect more than a billion people in 149 countries worldwide. It makes the case for domestic investment to reach the targets of WHO’s Roadmap on NTDs... by 2020 and sustain enhanced, equitable access to high-quality coverage against these diseases to 2030.
Th is third WHO report anticipates the investments needed as countries graduate from
low-income to middle-income status and as the world’s focus expands from the Millennium Development Goals to the Sustainable Development Goals.
more
Website last accessed on 10.04.2023
Accessed on 10.04.2023
While virtually unheard of in developed countries, NTDs are a group of medically diverse parasitic and bacterial infectious diseases common in tropical and subtropical areas. NTDs affect more than 1.5 billion people annually, causing death, blindness, disfigurement, chroni...c pain, cognitive impairment and other long-term disabilities that create obstacles to education, employment, economic growth and overall
development. When measured in disability-adjusted life years (DALYs), the NTD burden is greater than malaria or tuberculosis.
more
The Pharmaceutical Forum of the Americas (PFA) has previously published guidelines and organised campaigns for community pharmacists on the prevention, detection and control of arbovirus infections in 2018 with a grant from the FIP Foundation for Pharmacy Education and Research. Building on that exp...ertise, FIP joined efforts with the PFA and is now publishing its first-ever handbook to support pharmacists in the
area of vector-borne diseases. As the integration of the regional forums in FIP advances, such collaborative projects are tangible results of an increasingly regionally informed and regionally targeted work by FIP.
more
Accessed on 10.04.2023
Information sheet - Diarrhoea control with ORS and Zink
Website last accessed on 14.04.2023
One of the ongoing challenges with neglected tropical diseases (NTDs) is that the discovery of medicines to treat them has been very slow. Current global programmes for NTDs largely depend on donated medicines, primarily to treat the world’s poorest people ... most of whom live in remote rural or in deprived urban settings.
WHO recently spoke to Mr Robert J. Gyurik, who discovered albendazole in 1972. He took us through the journey that led him to develop the compound.
more
Website last accessed on 14.04.2023
Health workers Luke (Kenya), Juliana (Colombia), and Shishu (India) share the same hope for their patients with leishmaniasis: simple, oral treatments. For the first time ever, it seems leishmaniasis research is moving from neglect to a sense of hope.
Website last accessed on 14.04.2023
The GARC Education Platform (GEP) is a set of free online courses developed to improve the skills and knowledge of people working in rabies awareness and prevention. Through the GEP, we aim to empower people to become rabies advocates, focal persons, and exper...ts across the globe. After completing each course, you become a certified graduate and receive a unique certificate of completion!
more